Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic Regulator Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HDAC2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HDAC2 Active Recombinant Protein (Catalytic Domain, aa 1-488); High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified, Theoretical MW ~55 kDa. | View HDAC2 Products |
| Gene Delivery | HDAC2 Promise-ORF / Lentivirus; Full-length ORF for stable cell lines, CMV promoter. | View HDAC2 Products |
| Benchmark Control | Anti-HDAC2 Reference Antibody; Recombinant rabbit monoclonal positive control for IP/WB. | View HDAC2 Products |
| Validator | HDAC2 siRNA Set (3 unique sequences); For knockdown verification and specificity controls. | View HDAC2 Products |
| Related Target A | HDAC1; Closest homolog, essential for isoform selectivity screening and dual-inhibition assays. | View HDAC1 Products |
| Related Target B | HDAC3; Subfamily specificity panel component for Class I discrimination. | View HDAC3 Products |
| Related Target C | HDAC6; Cytoplasmic deacetylase for off-target counter-screening (Class IIb). | View HDAC6 Products |
Critical Assay Challenges
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (HDAC1/2/3 discrimination) | Human HDAC1, HDAC2, HDAC3 ortholog proteins available with >95% purity, Sequence Verified by Mass Spec. |
| PROTAC Degradation Monitoring | Sequence Verified, Endotoxin Controlled native proteins for precise ternary complex binding assays. |
| Lack of Cellular Controls | Valid sequence Lentivirus / Promise-ORF included for stable cell line generation. |
| False Positives in Cellular Assays | Validated siRNA sets included for target specificity and phenotype rescue checks. |
| Catalytic Dead Mutant Controls | H142A/H143A Active Site Mutant Proteins available for negative control assays. |
| Resistance Mutation Profiling | Clinically relevant mutants Y306F (rs1042903) and A247V (rs17852888) provided for mechanism-of-resistance studies. |
| CNS Penetration & Subcellular Localization | HDAC2-EGFP Lentivirus for live-cell imaging of nuclear-cytoplasmic shuttling. |
Live HDAC2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HDAC2-selective therapeutics is intensifying as the limitations of pan-HDAC inhibitors (cardiotoxicity, thrombocytopenia, generic competition) drive demand for isoform-specific modulation. Major players are shifting focus from broad epigenetic modulation to HDAC2-specific inhibition for neurodegenerative indications (Alzheimer's, peripheral neuropathy) requiring CNS-penetrant selective targeting. The next wave of R&D also targets synthetic lethal combinations in BRCA-mutant cancers and hormone-resistant prostate tumors. Takeda, Regenacy, and Merck are advancing selective small molecules, while Arvinas and C4 Therapeutics pursue PROTAC degraders for solid tumors. First-generation pan-inhibitors (Celgene/BMS, Novartis) face patent cliffs, accelerating the transition to next-generation agents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule | Regenacy, Takeda, Merck, Syndax | Oncology, Alzheimer's, Peripheral Neuropathy | Isoform selectivity panel (HDAC1/2/3 discrimination) with high-purity homolog proteins. |
| PROTAC Degrader | Arvinas, C4 Therapeutics, Academic/Biotech | Solid Tumors (Synthetic Lethality) | Ternary complex formation; require purified HDAC2 ligand-binding domain (native fold). |
| Dual-Target Inhibitor | Various | Refractory Cancers, Inflammation | Binding kinetics; need sequence-verified recombinant enzyme for SPR/BLI. |
| Pan-HDAC Inhibitor (Legacy) | Celgene (BMS), Novartis | Hematological Malignancies | Resistance mutation profiling; catalytically dead mutants and clinical resistance variants (Y306F, A247V). |
Key Mutations and Resistance Mechanisms
Known single-nucleotide polymorphisms in HDAC2 (UniProt Q92769) include rs1042903 (Tyr306Phe) and rs17852888 (Ala247Val). These mutations, located near the catalytic active site (Y306 directly coordinates Zn2+; A247 lies in a loop region), can confer resistance to first-generation inhibitors and alter substrate specificity. TarMart provides recombinant proteins encoding these mutants for mechanism-of-resistance assays and second-generation drug development.